Pharma Two B Ltd.
Quick facts
Phase 3 pipeline
- Marketed Pramipexole ER · Neurology
Pramipexole is a dopamine D2/D3 receptor agonist that stimulates dopamine signaling in the brain to improve motor control and reduce symptoms of Parkinson's disease.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: